FibroBiologics (FBLG) News Today $2.81 -0.27 (-8.77%) (As of 11/14/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based TherapeuticsNovember 14 at 9:15 AM | globenewswire.comFibroBiologics Reports Q3 2024 Financial ResultsNovember 14 at 12:03 AM | tipranks.comHC Wainwright Reiterates "Buy" Rating for FibroBiologics (NASDAQ:FBLG)HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of FibroBiologics in a report on Wednesday.November 13 at 8:06 AM | marketbeat.comFibrobiologics, Inc.: FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13 at 5:30 AM | finanznachrichten.deFibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12 at 4:20 PM | globenewswire.comBrokers Offer Predictions for FibroBiologics Q3 EarningsFibroBiologics, Inc. (NASDAQ:FBLG - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of FibroBiologics in a research note issued on Wednesday, October 30th. HC Wainwright analyst M. Caufield forecasts that the company will posNovember 1, 2024 | marketbeat.comFibroBiologics initiated with a Buy at H.C. WainwrightOctober 31, 2024 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of FibroBiologics (FBLG) with Buy RecommendationOctober 31, 2024 | msn.comFibroBiologics: A Promising Investment in Immune Restoration and Biotech InnovationOctober 31, 2024 | markets.businessinsider.comFibroBiologics CFO Andersen ResignsOctober 30, 2024 | marketwatch.comFibroBiologics (NASDAQ:FBLG) Now Covered by HC WainwrightHC Wainwright started coverage on FibroBiologics in a report on Wednesday. They issued a "buy" rating and a $12.00 price target for the company.October 30, 2024 | marketbeat.comFibrobiologics, Inc.: FibroBiologics Announces Updates for Novel Artificial Thymus Organoid TechnologyOctober 29, 2024 | finanznachrichten.deFibroBiologics Announces Leadership Changes and New AppointmentsOctober 29, 2024 | markets.businessinsider.comFibroBiologics Announces Updates for Novel Artificial Thymus Organoid TechnologyOctober 29, 2024 | globenewswire.comFibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024October 28, 2024 | globenewswire.comFibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic DiseasesOctober 18, 2024 | globenewswire.comFibrobiologics, Inc.: FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent OfficeOctober 17, 2024 | finanznachrichten.deFibroBiologics Shares Rise After European Patent for Fibroblast Cancer TreatmentOctober 16, 2024 | marketwatch.comFibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent OfficeOctober 16, 2024 | globenewswire.comFibroBiologics, Inc. (NASDAQ:FBLG) Sees Significant Growth in Short InterestFibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 2,250,000 shares, a growth of 21.6% from the September 15th total of 1,850,000 shares. Based on an average daily volume of 420,300 shares, the days-to-cover ratio is presently 5.4 days. Currently, 8.4% of the shares of the company are short sold.October 14, 2024 | marketbeat.comFibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual SummitOctober 11, 2024 | globenewswire.comFibroBiologics (NASDAQ:FBLG) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comFibroBiologics to Present at 2024 Cell & Gene Meeting on the MesaSeptember 30, 2024 | globenewswire.comBionomics Limited (B1N0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comFIBROBIOLOGICS INC. (SG0.BE)September 19, 2024 | nz.finance.yahoo.comFibroBiologics Engages Southern Star Research as CRO in AustraliaSeptember 19, 2024 | globenewswire.comFibroBiologics, Inc. (NASDAQ:FBLG) Sees Large Growth in Short InterestFibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,500,000 shares, a growth of 33.9% from the August 15th total of 1,120,000 shares. Based on an average trading volume of 418,700 shares, the days-to-cover ratio is presently 3.6 days. Currently, 5.6% of the company's stock are sold short.September 16, 2024 | marketbeat.comFibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based TechnologySeptember 12, 2024 | globenewswire.comFund Evaluation Group LLC Makes New $5.27 Million Investment in FibroBiologics, Inc. (NASDAQ:FBLG)Fund Evaluation Group LLC acquired a new position in shares of FibroBiologics, Inc. (NASDAQ:FBLG - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,055,105 shares of the company's stock, vSeptember 8, 2024 | marketbeat.comFibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 6, 2024 | globenewswire.comEF Hutton Acquisition Co. I Upgrades FibroBiologics (NASDAQ:FBLG) to "Strong-Buy"EF Hutton Acquisition Co. I upgraded shares of FibroBiologics to a "strong-buy" rating in a research report on Wednesday.September 6, 2024 | marketbeat.comEF Hutton Initiates Coverage of FibroBiologics (FBLG) with Buy RecommendationSeptember 5, 2024 | msn.comCascade Financial Partners LLC Acquires Shares of 315,055 FibroBiologics, Inc. (NASDAQ:FBLG)Cascade Financial Partners LLC bought a new position in shares of FibroBiologics, Inc. (NASDAQ:FBLG - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 315,055 shares of the company's stock, valuedAugust 31, 2024 | marketbeat.comFibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based TechnologyAugust 20, 2024 | globenewswire.comFBLG: Proof-of-Concept Data for Artificial Thymus Technology…August 15, 2024 | finance.yahoo.comFibroBiologics, Inc. (NASDAQ:FBLG) CEO Purchases $16,235.00 in StockAugust 13, 2024 | insidertrades.comFibroBiologics, Inc. (NASDAQ:FBLG) Insider Hamid Khoja Acquires 10,000 SharesAugust 13, 2024 | insidertrades.comFibroBiologics (NASDAQ:FBLG) Stock Price Down 7.1%FibroBiologics (NASDAQ:FBLG) Shares Down 7.1%August 13, 2024 | marketbeat.comPete O'heeron Acquires 8,500 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) StockFibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) CEO Pete O'heeron bought 8,500 shares of the company's stock in a transaction on Monday, August 12th. The shares were acquired at an average price of $1.91 per share, with a total value of $16,235.00. Following the transaction, the chief executive officer now directly owns 6,056,647 shares in the company, valued at approximately $11,568,195.77. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.August 13, 2024 | marketbeat.comFibroBiologics Files 2024 Second Quarter ReportAugust 7, 2024 | globenewswire.comFibroBiologics, Inc.'s Lock-Up Period Set To Expire on July 29th (NASDAQ:FBLG)FibroBiologics' (NASDAQ:FBLG - Get Free Report) lock-up period will end on Monday, July 29th. FibroBiologics had issued 4,806,226 shares in its public offering on January 31st. The total size of the offering was $144,186,780 based on an initial share price of $30.00. After the end of FibroBiologics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.July 22, 2024 | marketbeat.comFibroBiologics to Present at JonesTrading Healthcare Summit 2024July 15, 2024 | globenewswire.comFibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid TechnologyJune 25, 2024 | globenewswire.comFibroBiologics Set to Join Russell 2000® IndexJune 13, 2024 | globenewswire.comFibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024June 6, 2024 | globenewswire.comFibroBiologics Announces 2024 Annual Meeting of StockholdersMay 15, 2024 | globenewswire.comFBLG Stock Earnings: FibroBiologics, Inc. – Common Stock Reported Results for Q1 2024May 15, 2024 | msn.comFibroBiologics Files 2024 First Quarter ReportMay 14, 2024 | globenewswire.comFibroBiologics to Present at the BIO International Convention 2024May 7, 2024 | globenewswire.comFibroBiologics files to sell 1.8M unitsApril 26, 2024 | msn.com Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW FBLG Media Mentions By Week FBLG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FBLG News Sentiment▼0.500.54▲Average Medical News Sentiment FBLG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FBLG Articles This Week▼82▲FBLG Articles Average Week Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZVRA News Today DNA News Today RGNX News Today FDMT News Today AQST News Today CCCC News Today CTNM News Today RNAC News Today GHRS News Today ESPR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FBLG) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
